学 术 报 告:Protein tyrosine kinase inhibitors (Tinibs) for the prevention of diabetes and its complications

题  目：Protein tyrosine kinase inhibitors (Tinibs) for the prevention of diabetes and its complications

主讲人：Prof. Peter J. Little, B. Pharm., Ph. D., AM

澳大利亚生物脉管学会会长

Diabetes and Cell Biology实验室主任

主持人：陶亮 中山医学院药理教研室主任、教授,

        郑文华 中山大学药学院 教授

时   间：2009年5月6日（星期四） 上午10:00时

地   点：中山大学北校区永生楼四楼讲学厅

摘要:

Diabetes occurs in two major forms – immuno-compromised Type 1 and obesity and insulin resistant dependent Type 2 diabetes. Both forms are characterized and diagnosed by hyperglycemia. The diabetic milieu drives accelerated atherosclerosis leading to premature death from cardiovascular disease (CVD). Therapies aimed at reducing blood glucose lack persistent efficacy against the primary metabolic target (hyperglycemia) and have little or no efficacy in the prevention of CVD. New therapies are urgently needed for the prevention and treatment of diabetes and its complications. A family of protein tyrosine kinase (PTK) inhibitors known as tinibs and represented by the prototypical imatinib have shown efficacy in the prevention and reversal of diabetes in animal models and in attenuating hyperglycemia in humans. Our own research has pointed to the potential for tinibs to prevent CVD raising the possibility that this class of agent may be useful for the prevention of diabetes and its cardiovascular complications.

Peter教授简介：

Peter J Little教授是世界知名的心脏和糖尿病专家，就职于国际知名的科研机构——澳大利亚墨尔本Baker IDI心脏和糖尿病研究所，现任澳大利亚生物脉管学会会长和Diabetes and Cell Biology实验室主任，是澳大利亚心脏科学和糖尿病学科的学科带头人，澳大利亚Monash University荣誉教授及Royal Melbourne Institute of Technology University兼职教授，他致力于促进心脏科学心血管药物研究等方面的发展,为此作出了重要贡献并在澳大利亚及世界上获得多种奖项。现担任“nutrition”等多家国际知名杂志编辑和审稿人，撰写多篇高影响因子的论文发表于circulation， J Biol Chem， Cell Mol Life Sci， J Cell Mol Med， Atherosclerosis， Curr Opin Lipidol，等高水平杂志上。

欢迎各位师生踊跃参加！

中山大学中山医学院

中山大学医学科学处